

Corrections

In the article entitled “The Early Growth Response Gene *Egr2* (Alias *Krox20*) Is a Novel Transcriptional Target of Transforming Growth Factor- β That Is Up-Regulated in Systemic Sclerosis and Mediates Profibrotic Responses” (Volume 178, pages 2077–2090 of the May 2011 issue of *The American Journal of Pathology*), the third author’s name was listed incorrectly. The correct name is Swati Bhattacharyya.

In the article entitled “AP-1-Mediated M2 Macrophage Infiltration Underlies IL-1 β -but Not VEGF-A-Induced Lymphatic and Angiogenesis” (Volume 178, pages 1913–1921 of the April 2011 issue), HLECs were defined incorrectly. The correct expansion for HLECs is human lymphatic endothelial cells. This error occurred in the print article only; the online (HTML and PDF) versions of this article appear correctly.

In the article entitled “NF- κ B Inhibition Protects against Tumor-Induced Cardiac Atrophy *in Vivo*” (Volume 178, pages 1059–1068 of the March 2011 issue), the fourth author’s name was listed incorrectly. The correct name is Luge Li.

In the article entitled “Bone Marrow-Derived Progenitor Cells Do Not Contribute to Podocyte Turnover in the Puro-mycin Aminoglycoside and Renal Ablation Models in Rats” (Volume 178, pages 494–499 of the February 2011 issue), the fourth author’s surname was listed incorrectly. The correct surname name is Agustian. In addition, the author affiliation for Jan U. Becker contained errors. The correct author affiliation is Institute of Pathology, Hannover Medical School, Hannover, Germany.

In the article entitled “CD4⁺ T Cells Sensitized by Vascular Smooth Muscle Induce Vasculitis, and Interferon Gamma Is Critical for the Initiation of Vascular Pathology” (Volume 177, pages 3215–3223 of the December 2010 issue), panel B was inadvertently duplicated as panel C in Figure 1.

In the article entitled “ β -Cell Loss and β -Cell Apoptosis in Human Type 2 Diabetes Are Related to Islet Amyloid




Figure 1. Vasculitis incidence after transfer of SMC-sensitized lymphocytes is similar in wt and in B cell-deficient (JhD) mice. **A–C.** Vasculitis incidence scored on H&E sections of lung (each diamond depicts a mouse; horizontal bar is average). Control indicates noninjected mice. **A:** Adoptive transfer of wt BALB/c lymphocytes previously sensitized by co-culture (wt mL) with syngeneic SMC to wt BALB/c recipient mice; $n = 11$, $P = 0.003$ (four experiments). SM are mice injected with primary smooth muscle cultures (10^6 cells/mouse). Ly are mice injected with isolated naive spleen lymphocytes (5×10^6 cells/mouse). **B:** Transfer of sensitized wt BALB/c lymphocytes to RAG-2-deficient mice; $n = 7$, $P = 0.006$ (three experiments). **C:** Transfer of sensitized JhD lymphocytes to JhD mice; $n = 12$ mice, $P = 0.00002$ (seven experiments). **D:** H&E staining of 4- μ m paraffin section of lung 7 days after vasculitis induction in JhD mouse, showing blood vessels with granulomatous-like inflammation and infiltration of leukocytes with destruction of vessel wall. L indicates vessel lumen. Scale bar = 20 μ m. Original magnification, $\times 400$.

Deposition” (Volume 178, pages 2632–2640 of the June 2011 issue), Table 2 contained errors in the definition of NA. The corrected Table 2, which correctly distinguishes between parameters with no data (ND) and those with data not applicable (NA), is shown below.

Table 2. Clinicodemographic Characteristics of Individual Subjects

Age (years)/ Sex	BMI (kg/m ²)	Blood glucose (mmol/L)	Diabetes duration (years)	Diabetes medication	Cause of death
Diabetes group					
62/F	30.9	8.53	ND	glyburide, insulin	pulmonary embolism
78/F	28.3	7.67	2	diet	GI hemorrhage
59/M	32.6	7.90	8	insulin	cardiac arrest

(table continues)

Table 2. *Continued*

Age (years)/ Sex	BMI (kg/m ²)	Blood glucose (mmol/L)	Diabetes duration (years)	Diabetes medication	Cause of death
59/M	38.4	7.39	ND	insulin	leukemia
69/F	21.2	9.50	ND	metformin	malignancy
81/M	31.4	5.63	ND	glyburide, metformin	aortic dissection
68/M	27.2	11.42	ND	metformin	GI hemorrhage
52/M	26.3	9.07	ND	none	cardiopulmonary failure
61/M	29.7	6.85	14	insulin	respiratory failure
71/F	21.3	9.39	10	glyburide	coronary artery disease
51/F	41.2	11.11	ND	glyburide, insulin	malignancy
62/M	35.9	7.46	ND	insulin in TPN	abdominal hemorrhage
80/F	29.1	8.89	20	acetohexamide,insulin	coronary artery disease
61/M	36.3	8.92	12	diet, glipizide	sepsis
58/M	34.4	8.29	ND	insulin	coronary artery disease
71/M	37.5	6.50	27	insulin	postoperative complications
74/F	36.0	13.17	ND	unknown	aspiration pneumonia
37/M	39.7	7.69	3	unknown	cardiomyopathy
71/F	21.6	ND	12	glyburide	coronary artery disease
70/F	32.8	10.33	ND	oral hypoglycemic, unspecified	abdominal hemorrhage
69/M	21.3	7.06	10	glyburide	coronary artery disease
64/M	22.5	6.47	ND	insulin	sepsis
40/M	41.2	10.17	ND	diet, metformin	postoperative complications
28/M	35.8	7.67	1	metformin	myelodysplastic syndrome
82/M	25.6	17.06	ND	glipizide	sepsis
63/F	38.8	10.50	12	insulin	malignancy
63/M	26.5	7.11	ND	diet	malignancy
68/M	25.0	NA	ND	diet	cardiac arrest
82/M	19.0	7.50	2	diet	sepsis
Control group					
87/F	33.0	5.14	NA	NA	valvular heart disease
62/M	23.4	5.58	NA	NA	malignancy
34/M	17.5	5.14	NA	NA	malignancy
63/F	18.7	5.23	NA	NA	malignancy
54/F	49.3	5.94	NA	NA	postoperative complications
82/F	40.9	4.72	NA	NA	perforated duodenal ulcer
61/F	24.3	5.58	NA	NA	abdominal hemorrhage
65/M	20.5	6.31	NA	NA	stroke
21/F	32.2	4.63	NA	NA	pulmonary embolism
64/M	18.7	6.47	NA	NA	malignancy
65/F	40.1	4.79	NA	NA	pulmonary veno-occlusive disease
67/M	24.1	5.12	NA	NA	malignancy
52/M	24.1	5.26	NA	NA	malignancy
77/F	26.3	6.08	NA	NA	sepsis
34/M	28.8	5.44	NA	NA	malignancy
68/F	18.6	4.86	NA	NA	malignancy
89/M	17.8	6.07	NA	NA	malignancy
57/F	19.2	5.87	NA	NA	malignancy
75/M	22.6	4.94	NA	NA	pneumonia
66/F	25.7	5.43	NA	NA	respiratory failure
50/M	28.0	5.50	NA	NA	cardiac failure
45/M	29.8	4.53	NA	NA	cardiac arrest
83/F	19.8	5.15	NA	NA	cardiac arrest
44/F	18.0	5.18	NA	NA	meningitis
20/F	22.8	4.60	NA	NA	pulmonary hypertension
42/F	34.0	5.39	NA	NA	sepsis
88/F	29.2	6.16	NA	NA	respiratory failure
81/M	27.1	5.56	NA	NA	respiratory failure
58/M	24.9	5.44	NA	NA	stroke
19/M	32.7	6.22	NA	NA	malignancy
46/F	28.1	6.47	NA	NA	sepsis
78/F	42.4	3.78	NA	NA	abdominal hemorrhage
75/M	20.9	5.83	NA	NA	malignancy
72/M	34.9	5.56	NA	NA	multiple myeloma
82/M	32.5	6.06	NA	NA	sepsis
94/M	21.9	5.22	NA	NA	sepsis
68/M	24.0	5.17	NA	NA	respiratory failure
60/M	15.9	6.94	NA	NA	respiratory failure
57/M	22.8	5.56	NA	NA	cardiac arrest

F, female; GI, gastrointestinal; M, male; ND, no data; NA, not applicable; TPN, total parenteral nutrition.